|30 Rockefeller Plz, 58th Fl , New York, NY 10112|
|Fund Manager||Team Managed|
The Portfolio seeks long-term capital appreciation. The Investment Manager allocates the Portfolios assets among various emerging markets equity strategies managed by the Investment Manager(and other emerging markets equity securities held in other strategies managed by the Investment Manager) in proportions consistent with the Investment Managers evaluation of various economic and other factors through quantitative and qualitative analysis. These proportions are changed from time to time without notice to shareholders, and at any given time the allocation to one strategy, market sector, region or country may comprise a substantial percentage of the Portfolios assets, or conversely, there may be no allocation to any such strategy, market sector, region or country. The Investment Manager will make allocation and securities selection decisions based on quantitative and qualitative analysis using number of different tools, including proprietary software models. Quantitative analysis includes statistical analysis of portfolio risks, factor dependencies and trading tendencies. Qualitative analysis includes analysis of the global economic environment as well as internal and external research on individual securities, portfolio holdings, attribution factors, behavioral patterns and overall market views and scenarios. The Investment Manager may consider a securitys value or growth characteristics in selecting investments for the Portfolio and may invest in securities of any size or market capitalization. The equity securities in which the Portfolio invests may be denominated in the US dollar, the Canadian dollar, the Euro, the Japanese yen, the Pound Sterling, or the local currency of the issuer. Under normal circumstances, the Portfolio invests at least 80% of its assets in equity securities of companies whose principal business activities are located in emerging market countries. In addition to common stocks, such equity securities also may include American Depositary Receipts (ADRs), Global Depositary Receipts and European Depositary Receipts. Emerging market countries include all countries not represented by the MSCI World Index. The allocation of the Portfolios assets among countries and regions may vary from time to time based on the Investment Managers judgment and its analysis of market conditions.
|Asset Type||% Of Allocation|
|Total Net Assets||62.39 M|
|Criteria||3 Years||5 Years||10 Years|
|Minimum Initial IRA||$0|
|Timeframe||Average Annual Current Performance Monthly As Of 09/30/2021||Average Annual Current Performance Quarterly As Of 09/30/2021||Avg Annual Current Performance Monthly As Of 09/30/2021||Avg Annual Current Performance Quarterly As Of 09/30/2021|
|Life Of Fund||
|Symbol||Company Name||% Of Assets|
|TSM||TAIWAN SEMICONDUCTOR MANUFACT||4.63%|
|BABA.N||ALIBABA GROUP HOLDING LTD||3.50%|
|0700.HK||TENCENT HOLDINGS LTD||3.02%|
|TCS.NS||TATA CONSULTANCY SERVICES LTD||2.67%|
|RLNIY||RELIANCE INDUSTRIES LTD||2.47%|
|AAL:LN||ANGLO AMERICAN PLC||2.30%|
|000660||SK HYNIX INC||2.29%|
Master The Market with the Help of Our Financial Experts
Atea Pharmaceuticals could shed more than $2 billion in value Tuesday after the drugmaker said a mid-stage trial of its developing COVID treatment failed to meet expectations.
Cloud-software growth stocks have been a bright spot in an uncertain market. Investors might look closely at Cloudflare and Digital Ocean.
Philip Morris posts a third-quarter earnings beat as sales of its smokeless non-tobacco products continue strong, though cautions on supply chain impact.
Travelers Companies posts third-quarter earnings that exceed analysts’ forecasts as a drop in what it calls ‘catastrophic losses’ offsets record net written premiums.
Solid third quarters continue to power stocks higher Tuesday, even as growth and inflation signals remain stubbornly persistent as oil prices top $85 a barrel in overnight trading.
Procter & Gamble held its 2022 forecasts in place, seeing sales growth of between 2% and 4%, following stronger-than-expected first quarter earnings.
Johnson & Johnson said it sees 2021 vaccine sales of $2.5 billion, with overall revenues rising to between $94.1 billion to $94.6 billion, following its Q3 earnings beat.
Stocks edge higher ahead of earnings; SEC says GameStop surge powered by believers; FDA set to approve "mix & match' COVID boosters; DraftKings faces Entain bid deadline and Rent the Runway seeks $1.3 billion valuation in Nasdaq IPO.